Related Experiment Video
Updated: Jul 30, 2025
Cell Death Associated with Abnormal Mitosis Observed by Confocal Imaging in Live Cancer Cells
Published on: August 21, 2013
[PARP inhibitors - A better selection of patients]
Marc Senglet1, Grégoire Berthod2, Marie-Gabrielle Courtes2
1Service d'oncologie, Hôpitaux universitaires de Genève, 1211 Genève 14.
Abstract:
PARP inhibitors (PARPi) have established themselves as a class of essential anti-cancer drugs. They inhibit PARP proteins involved in DNA damage repair. Their anti-tumor action requires a concomitant abnormality in DNA damage repair, the homologous recombination deficiency (HRD). The genomic instability being too substantial, the tumor cell goes into apoptosis (concept of synthetic lethality). This last decade, the selection of patients benefiting from PARPi has been refined with convincing results for ovarian cancers, but also breast, prostate and pancreatic cancers. This article presents recent data that have impacted our clinical practice and the PARPi authorized in Switzerland.
Insights
Poly (ADP-ribose) polymerase inhibitors (PARPi) are crucial anti-cancer drugs that target DNA repair mechanisms. They are effective in tumors with homologous recombination deficiency (HRD), leading to cancer cell death.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Context:
- PARP inhibitors (PARPi) represent a significant advancement in cancer therapy.
- Their efficacy is linked to homologous recombination deficiency (HRD), a state of impaired DNA repair.
- PARPi leverage synthetic lethality to induce apoptosis in cancer cells with substantial genomic instability.
Purpose:
- To review recent clinical data and authorized PARP inhibitors (PARPi) in Switzerland.
- To highlight advancements in patient selection for PARPi therapy.
- To discuss the impact of recent findings on clinical practice.
Summary:
- PARP inhibitors (PARPi) are effective anti-cancer agents that function by inhibiting PARP proteins crucial for DNA damage repair.
- The anti-tumor activity of PARPi is contingent upon the presence of homologous recombination deficiency (HRD), leading to synthetic lethality.
- Recent data have refined patient selection, showing efficacy in ovarian, breast, prostate, and pancreatic cancers.
Impact:
- Recent data have refined patient selection for PARPi therapy, improving outcomes.
- The article discusses PARPi authorized for use in Switzerland.
- Clinical practice has been significantly impacted by these advancements in targeted cancer therapy.
